Compare AbbVie Inc (ABBV) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs LyondellBasell Industries NV — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while LyondellBasell Industries NV trades at $56.01 (market cap $17.62B). The key difference: AbbVie Inc is far larger — about 25.5× LyondellBasell Industries NV's market cap, and LyondellBasell Industries NV pays the higher dividend (7.55%). Which is the better fit depends on your goals.
| ABBV | LYB | |
|---|---|---|
Market Cap | $449.91B | $17.62B |
Sector | Health | Basic Materials |
52-Week High | $261.07 | $82.38 |
52-Week Low | $184.85 | $42.28 |
Enterprise Value | $513.38B | $29.24B |
Dividend Yield | 2.72% | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
LyondellBasell (LYB) trades at $54.61, up 2.33% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$745M in 2025 with revenue declining to $30.15B, though it beat EPS estimates in two of the last three quarters. Recent news highlights a packaging collaboration with Mondelez and upcoming Q2 2026 earnings on July 31. Cash flow remains positive with $61M net inflow in 2025, while debt-to-asset ratio increased to 38.18%.
Outlook is mixed: analyst consensus price target of $73.11 suggests 34% upside, supported by cost-cutting and recycling initiatives, but persistent margin pressures and high debt pose risks. Investors should weigh the value opportunity (P/S of 0.57) against earnings volatility and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
